vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone336-841-0300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$12.43 million
Profitability
Miscellaneous
Employees52
Next Earnings Date8/2/2019 (Estimated)
OptionableNot Optionable
vTv Therapeutics (NASDAQ:VTVT) Frequently Asked Questions
What is vTv Therapeutics' stock symbol?
vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."
How were vTv Therapeutics' earnings last quarter?
vTv Therapeutics Inc (NASDAQ:VTVT) released its earnings results on Wednesday, May, 1st. The biotechnology company reported ($0.26) earnings per share for the quarter. The biotechnology company had revenue of $0.92 million for the quarter. View vTv Therapeutics' Earnings History.
When is vTv Therapeutics' next earnings date?
What price target have analysts set for VTVT?
2 equities research analysts have issued 1 year target prices for vTv Therapeutics' shares. Their predictions range from $3.00 to $5.00. On average, they expect vTv Therapeutics' share price to reach $4.00 in the next twelve months. This suggests a possible upside of 177.8% from the stock's current price. View Analyst Price Targets for vTv Therapeutics.
What is the consensus analysts' recommendation for vTv Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for vTv Therapeutics.
What are Wall Street analysts saying about vTv Therapeutics stock?
Here are some recent quotes from research analysts about vTv Therapeutics stock:
- 1. HC Wainwright analysts commented, "Our $5 PT was derived by using a weighted-average cost of capital of 24% for vTv to discount free cash flows from annual sales and royalty payments of azeliragon and TPP399 for each year and dividing them by our projected number of shares for each year to account for the effects of share dilution, and then factoring in a 1% terminal growth rate and 26% clinical program probability of success." (6/7/2019)
- 2. According to Zacks Investment Research, "vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. " (5/2/2019)
- 3. Northland Securities analysts commented, "We anticipate details to be forthcoming. Trials: vTv Therapeutics indicated in its 10K filing (2/26 post-close) that the Company has initiated start-up activities for an adaptive P2/P3 trial evaluating azeliragon for treatment of mild Alzheimer’s disease (AD) patients with type 2 diabetes. We anticipate the P2 study will likely be comprised of ~100 subjects with mild AD and A1c levels at/above 6.5%, with ~6 month patient dosing. Based upon the previously released subgroup analysis of AD patients with type 2 diabetes in its large P3 STEADFAST Part A study (See Below), we believe a P2 trial w/ ~100 subjects and six month dosing would be sufficient to demonstrate clinical benefit to potentially support a P3 study." (2/27/2019)
Has vTv Therapeutics been receiving favorable news coverage?
News articles about VTVT stock have been trending somewhat positive on Monday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. vTv Therapeutics earned a daily sentiment score of 1.4 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for vTv Therapeutics.
Who are some of vTv Therapeutics' key competitors?
Some companies that are related to vTv Therapeutics include Zynerba Pharmaceuticals (ZYNE), Protagonist Therapeutics (PTGX), Cyclerion Therapeutics (CYCN), American Brivision (Holding) (ABVC), Molecular Templates (MTEM), Dova Pharmaceuticals (DOVA), Athersys (ATHX), Xeris Pharmaceuticals (XERS), XBiotech (XBIT), Abeona Therapeutics (ABEO), Concert Pharmaceuticals (CNCE), Chiasma (CHMA), Dynavax Technologies (DVAX), Urovant Sciences (UROV) and Verrica Pharmaceuticals (VRCA).
What other stocks do shareholders of vTv Therapeutics own?
Who are vTv Therapeutics' key executives?
vTv Therapeutics' management team includes the folowing people:
- Mr. Jeffrey B. Kindler, Exec. Chairman (Age 63)
- Mr. Stephen L. Holcombe, Pres & CEO (Age 62)
- Mr. Rudy C. Howard CPA, B.A., CPA, Exec. VP & CFO (Age 61)
- Dr. Carmen Valcarce Ph.D., Chief Scientific Officer & Exec. VP
- Ms. Robin E. Abrams, Exec. VP & Gen. Counsel (Age 55)
When did vTv Therapeutics IPO?
(VTVT) raised $125 million in an initial public offering (IPO) on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.
Who are vTv Therapeutics' major shareholders?
vTv Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Wedbush Securities Inc. (0.04%). Company insiders that own vTv Therapeutics stock include Paul G Savas and Ronald O Perelman. View Institutional Ownership Trends for vTv Therapeutics.
Which major investors are buying vTv Therapeutics stock?
VTVT stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought vTv Therapeutics stock in the last two years include Paul G Savas and Ronald O Perelman. View Insider Buying and Selling for vTv Therapeutics.
How do I buy shares of vTv Therapeutics?
Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is vTv Therapeutics' stock price today?
One share of VTVT stock can currently be purchased for approximately $1.44.
How big of a company is vTv Therapeutics?
vTv Therapeutics has a market capitalization of $72.46 million and generates $12.43 million in revenue each year. The biotechnology company earns $-7,910,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. vTv Therapeutics employs 52 workers across the globe.View Additional Information About vTv Therapeutics.
What is vTv Therapeutics' official website?
How can I contact vTv Therapeutics?
vTv Therapeutics' mailing address is 4170 MENDENHALL OAKS PKWY, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected]
MarketBeat Community Rating for vTv Therapeutics (NASDAQ VTVT)
MarketBeat's community ratings are surveys of what our community members think about vTv Therapeutics and other stocks. Vote "Outperform" if you believe VTVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTVT will underperform the S&P 500 over the long term. You may vote once every thirty days.
